Potent, Persistent Induction and Modulation of Cellular Immune Responses in Rhesus Macaques Primed with Ad5hr-Simian Immunodeficiency Virus (SIV)
env/rev
,
gag
, and/or
nef
Vaccines and Boosted with SIV gp120
Abstract:Immunity elicited by multicomponent vaccines delivered by replication-competent Ad5hr-simian immunodeficiency virus (SIV) recombinants was systematically investigated. Rhesus macaques were immunized mucosally at weeks 0 and 12 with Ad5hr-SIV smH4 env/rev, with or without Ad5hr-SIV mac239 gag or Ad5hr-SIV mac239 nef, or with all three recombinants. The total Ad5hr dosage was comparably adjusted among all animals with empty Ad5hr-⌬E3 vector. The macaques were boosted with SIV gp120 in monophosphoryl A-stable emu… Show more
“…Protective efficacy has also been observed in rhesus macaques that have been challenged vaginally or rectally with pathogenic SIV (19,20,22,25). In our most recent Ad-SIV/gp120 vaccine efficacy study, a strong level of protection against an intrarectal SIV mac251 challenge was achieved (24,25). Notably, gp120-binding Ab titers and anti-envelope and anti-Rev cellular immune responses significantly correlated with reduced acute and setpoint viral loads, respectively (25).…”
Effector cells armed with Abs can eliminate virus-infected target cells by Ab-dependent cellular cytotoxicity (ADCC), an immune mechanism that has been largely overlooked in HIV vaccine development. Here, we show that a prime/boost AIDS vaccine approach elicits potent ADCC activity correlating with protection against SIV in rhesus macaques (Macacca mulatta). Priming with replicating adenovirus type 5 host range mutant-SIV recombinants, followed by boosting with SIV gp120, elicited Abs with ADCC activity against SIVmac251-infected cells. In vitro ADCC activity correlated with in vivo reduced acute viremia after a mucosal challenge with pathogenic SIV. Our findings expose ADCC activity as an immune correlate that may be relevant in the rational design of an efficacious vaccine against HIV.
“…Protective efficacy has also been observed in rhesus macaques that have been challenged vaginally or rectally with pathogenic SIV (19,20,22,25). In our most recent Ad-SIV/gp120 vaccine efficacy study, a strong level of protection against an intrarectal SIV mac251 challenge was achieved (24,25). Notably, gp120-binding Ab titers and anti-envelope and anti-Rev cellular immune responses significantly correlated with reduced acute and setpoint viral loads, respectively (25).…”
Effector cells armed with Abs can eliminate virus-infected target cells by Ab-dependent cellular cytotoxicity (ADCC), an immune mechanism that has been largely overlooked in HIV vaccine development. Here, we show that a prime/boost AIDS vaccine approach elicits potent ADCC activity correlating with protection against SIV in rhesus macaques (Macacca mulatta). Priming with replicating adenovirus type 5 host range mutant-SIV recombinants, followed by boosting with SIV gp120, elicited Abs with ADCC activity against SIVmac251-infected cells. In vitro ADCC activity correlated with in vivo reduced acute viremia after a mucosal challenge with pathogenic SIV. Our findings expose ADCC activity as an immune correlate that may be relevant in the rational design of an efficacious vaccine against HIV.
“…Significant Env, Rev, Gag and Nef specific cellular immune responses were elicited according to immunization groups throughout the priming and boosting phases of the vaccine regimen [93]. Interestingly, the addition of Ad5hr-SIVgag to the Ad5hr-HIVenv immunization regimen enhanced Env-specific responses, whereas Nef-specific responses were transiently downmodulated in the priming phase when all three recombinants were given together.…”
Section: Prime/boost Approaches Using Ad Replicating Vectorsmentioning
confidence: 95%
“…For example, chimpanzees have been administered 10 7 to 10 8 plaque forming units (pfu) intranasally [77,116,127] while a safe dose in humans is no more than 10 4 [128]. Similarly, using the Ad5hr vector in macaques, doses of 10 9 have been administered intranasally and intratracheally with no clinical consequences [88,93,102]. Duration of shedding of Ad vector in stool samples is also used to estimate Ad replicability in vivo.…”
Background-In the last few years the HIV vaccine field has moved forward a number of promising vaccine candidates into human clinical trials.Objective-In this review we briefly discuss the advances made in vaccine development and HIV pathogenesis and give an overview of the body of work our lab has generated in multiple animal models on replication-competent Ad recombinant vaccines.Methods-Emphasis is placed on comparative examination of vaccine components, routes of immunization and challenge models using replicating Ad vectors.Results/conclusion-The overall findings make the case that replicating Ad vectors are superior in priming multiple arms of the immune system, and in conjunction with protein boosting, have resulted in dramatic protective efficacy leading to their advancement to phase 1 trials. Implications of the recent halting of the Merck Ad5-HIV phase 2b clinical trial for our vaccine approach and other vectored vaccines are discussed.
“…PBMCs secreting gamma interferon (IFN-γ) in response to overnight stimulation with a single pool of Tat 15-mers (1 μg/ml each) were enumerated using ELISPOT kits (U-Cytech, Utrecht, The Netherlands) as described [50]. Assays were performed in triplicate; background spots in wells containing only medium (RPMI 1640 containing 5% fetal calf serum, 1 mM L-glutamine, 100 U/ml penicillin, and 100 μg/ml streptomycin) were subtracted.…”
Section: Elispot Assaymentioning
confidence: 99%
“…Freshly isolated PBMC (10 5 cells/well) were cultured for five days in triplicate in 200 μl of RPMI 1640 medium containing 10% fetal calf serum (FCS), 1mM L-glutamine and 100 U/ml penicillin, 100μg/ml streptomycin (R-10) with 1μg of oxidized Tat /well at 37°C. On the fifth day, cells were pulsed overnight with 3 H-thymidine (1μCi/well), harvested and counted as described [50]. Stimulation indices (SI) were calculated by dividing mean counts per minute (cpm) with Tat by mean cpm with R-10 plus degassed buffer.…”
Protection afforded by HIV Tat-based vaccines has differed in Indian rhesus and Mauritian cynomolgus macaques. We evaluated native Tat and Ad-HIVtat priming/Tat-boosting regimens in both species. Both vaccines were immunogenic. Only the Ad-tat regimen modestly reduced acute viremia in rhesus macaques after SHIV 89.6P challenge. Confounding variables uncovered in Mauritian macaques included significant associations of susceptibility to infection with MHC class IB and class II H2 and H5 haplotypes, and resistance to infection with class IB haplotypes H3 and H6. Although protection here was limited, Tat-based vaccines incorporating other HIV components have shown greater efficacy. Combination strategies should be further explored.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.